Agents for Diagnostic Use: Radiopaque Media
IPRIM3 “Primovist injection” 0.25 mmol/ml; 10 ml/syringe
適應症：適用於T1加權掃描核磁造影時，偵測肝臟局部病灶及提供病灶特性資訊。本品僅為診斷所用，限以靜脈注射。
Usual dose:
Intravenous route: MRI of liver :
0.1 mL/kg (0.025 millimoles/kg) given undiluted as a single IV bolus injection at a flow rate of approximately 2 mL/sec
Dose adjustment:
In Renal Failure:
GFR < 30 mL/min/1.73m2: avoid use.
If use is required when no other modalities can provide the necessary diagnostic information, do not exceed the recommended dose and allow sufficient time for elimination of gadoxetate sodium before readministration.
During Dialysis
Hemodialysis: Consider prompt initiation of hemodialysis after administration of gadoxetate sodium to enhance elimination.
In Other Disease States
In patients with elevated intrinsic bilirubin (greater than 3 mg/dL) or ferritin levels (including those caused by hemodialysis), perform imaging no longer than 60 minutes after administration of gadoxetate sodium.
Contraindication:
Hypersensitivity reactions, severe, to gadoxetate sodium
Precaution:
Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with:
Acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2), or
Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period,
Adverse effect:
Common: nausea, headache, feeling hot, blood pressure increased and dizziness
Serious:anaphylactoid shock